Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
Ann Surg Oncol. 2018 May;25(5):1160-1166. doi: 10.1245/s10434-018-6354-4. Epub 2018 Feb 5.
BACKGROUND: Sarcopenia is recognized as an important prognostic factor in various types of cancer, including gastric cancer. While long-term survival analyses typically focus on overall and disease-specific survival, death from other causes has received far less attention. METHODS: We reviewed medical records of 491 gastric cancer patients who underwent gastrectomy from January 2005 to March 2014 and whose preoperative computed tomography (CT) images were available for evaluation of sarcopenia. Sarcopenia was defined as the SMA/BSA index (skeletal muscle area divided by body surface area) below the sex-specific lowest quartile. RESULTS: Sarcopenia was significantly associated with age, high body mass index (BMI), presence of comorbidity, high American Society of Anesthesiologists physical status (ASA-PS), high T score, advanced stage, large blood loss, and long hospital stay, but was not significantly associated with postoperative complications. Univariate and multivariate analyses of prognostic factors for overall survival revealed that sarcopenia is an independent predictor of poor prognosis [hazard ratio (HR) 1.46, 95% confidence interval (CI) 1.01-2.09, p = 0.0454]. Our analysis of death due to other causes found that non-gastric cancer-related deaths were more frequent among sarcopenia patients with comorbidities than in the rest of our study population (p = 0.0001), while univariate and multivariate analyses revealed that sarcopenia with comorbidity was an independent risk factor for non-gastric cancer-related death (HR 1.84, 95% CI 1.31-3.61, p = 0.0308), as was age. CONCLUSION: For gastric cancer patients, sarcopenia increases the risk of death from other causes following surgery, which reveals the importance of developing treatment strategies based not only on cancer status but also on other clinical factors, including sarcopenia and comorbidity.
背景:肌肉减少症被认为是各种类型癌症(包括胃癌)的重要预后因素。虽然长期生存分析通常侧重于总生存和疾病特异性生存,但其他原因导致的死亡却很少受到关注。
方法:我们回顾了 2005 年 1 月至 2014 年 3 月期间接受胃切除术的 491 例胃癌患者的病历记录,这些患者的术前计算机断层扫描(CT)图像可用于评估肌肉减少症。肌肉减少症定义为 SMA/BSA 指数(骨骼肌面积除以体表面积)低于性别特异性最低四分位数。
结果:肌肉减少症与年龄、高体重指数(BMI)、合并症存在、美国麻醉医师协会身体状况评分(ASA-PS)高、T 评分高、晚期、大量失血和住院时间长显著相关,但与术后并发症无显著相关性。总体生存预后因素的单因素和多因素分析显示,肌肉减少症是预后不良的独立预测因素[风险比(HR)1.46,95%置信区间(CI)1.01-2.09,p=0.0454]。我们对其他原因导致的死亡的分析发现,合并症患者中与胃癌无关的死亡较其他研究人群更为常见(p=0.0001),而单因素和多因素分析显示,合并症的肌肉减少症是与胃癌无关的死亡的独立危险因素(HR 1.84,95%CI 1.31-3.61,p=0.0308),年龄也是如此。
结论:对于胃癌患者,手术后肌肉减少症增加了因其他原因导致死亡的风险,这表明不仅要根据癌症状况,还要根据其他临床因素(包括肌肉减少症和合并症)制定治疗策略的重要性。
BMC Cancer. 2025-3-10
Ann Gastroenterol Surg. 2024-3-16
World J Gastrointest Oncol. 2024-5-15
Curr Oncol Rep. 2016-10
CA Cancer J Clin. 2016-2-17